Enhancing cancer treatment by normal tissue protection

通过保护正常组织增强癌症治疗

基本信息

  • 批准号:
    8671485
  • 负责人:
  • 金额:
    $ 41.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-04-01 至 2019-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Background. 3,3'-Diindolylmethane (DIM) is a proposed cancer prevention agent that can be given safely to humans in oral form. We showed that DIM protects normal cells and tissues from damage by ionizing radiation. The protection is due, in part, by ATM activation and is potentially exploitable for protecting normal tissues and organs in the radiotherapy clinic. In preliminary studies, DIM did not protect human breast xenograft tumors in nude mice, but strongly protected mice and rats against supralethal doses of total body irradiation up to 13-Gy. Hypothesis. Here, we hypothesize that DIM activates an ATM-dependent cytoprotective DNA damage response (DDR) and antioxidant response without itself causing DNA damage or oxidative stress. We predict differential protection of normal cells relative to tumor cells in vivo because tumors already exhibit constitutive activation of a similar DDR-like pathway and of cellular survival pathways (e.g., AKT, NF-¿B, Bcl-2/Bcl-XL). Research design. We propose three specific aims to investigate DIM's mechanism of action and to advance DIM as a candidate clinical radiation protector during cancer treatment. The experimental plan will include studies to: 1) identify the molecular mechanism(s) of DIM radioprotection up- and down-stream of ATM by the use of biochemical, molecular biologic, and genetic approaches; 2) test the effects of DIM on tumor growth and tumor radiosensitivity in response to fractionated radiation treatments; and 3) test the ability of DIM to protect against late radiation effects in normal tissues, using established mouse models for lung and skin toxicity. Significance. The proposed research addresses the development of a novel means of radioprotection of normal tissues in cancer radiation therapy. The ultimate goal is to develop DIM as a clinical radioprotector in order to improve the therapeutic index by allowing higher doses of radiation to improve locoregional tumor control and/or by reducing late dose-limiting normal tissue toxicity at any given dose of radiation.
描述(由申请人提供):背景。3,3 '-二吲哚基甲烷(DIM)是一种建议的癌症预防剂,可以安全地口服给人类。我们发现,DIM保护正常细胞和组织免受电离辐射的损害。这种保护部分是由于ATM激活,并且可能可用于在放射治疗临床中保护正常组织和器官。在初步研究中,DIM不能保护裸鼠的人乳腺异种移植瘤,但能强烈保护小鼠和大鼠免受高达13-戈伊的超致死剂量全身照射。假说.在这里,我们假设,DIM激活ATM依赖的细胞保护性DNA损伤反应(DDR)和抗氧化反应,而本身不引起DNA损伤或氧化应激。我们预测在体内正常细胞相对于肿瘤细胞的差异保护,因为肿瘤已经表现出类似的 DDR样途径和细胞存活途径(例如,AKT、NF-κ B B、Bcl-2/Bcl-XL)。研究设计。我们提出了三个具体目标来研究DIM的作用机制,并推动DIM作为癌症治疗期间的候选临床辐射保护剂。实验计划将包括以下研究:1)通过使用生物化学、分子生物学和遗传学方法,确定DIM在ATM上游和下游的辐射防护的分子机制; 2)测试DIM对肿瘤生长和肿瘤对分次辐射治疗的辐射敏感性的影响;和3)使用已建立的小鼠肺和皮肤毒性模型,测试DIM保护正常组织免受晚期辐射影响的能力。意义拟议的研究解决了癌症放射治疗中正常组织辐射防护的新方法的发展。最终目标是开发DIM作为临床放射防护剂,以通过允许更高剂量的辐射来改善局部肿瘤控制和/或通过在任何给定剂量的辐射下减少晚期剂量限制性正常组织毒性来改善治疗指数。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eliot M. Rosen其他文献

Regulation of progesterone receptor signaling by BRCA1 in mammary cancer
BRCA1 对乳腺癌中孕酮受体信号传导的调节
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Pragati Katiyar;Yongxian Ma;Saijun Fan;R. Pestell;Priscilla A. Furth;Eliot M. Rosen
  • 通讯作者:
    Eliot M. Rosen
Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epi
肝细胞生长因子/分散因子对上皮细胞的影响。
  • DOI:
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    15.9
  • 作者:
    Asma Nusrat;C. Parkos;A. E. Bacarra;P. Godowski;C. Delp;Eliot M. Rosen;J. L. Madara
  • 通讯作者:
    J. L. Madara
P53-independent downregulation of p73 in human cancer cells treated with Adriamycin
  • DOI:
    10.1007/s002800000196
  • 发表时间:
    2001-02-01
  • 期刊:
  • 影响因子:
    2.300
  • 作者:
    Renqi Yuan;Qinghui Meng;Hao Hu;Itzhak D. Goldberg;Eliot M. Rosen;Saijun Fan
  • 通讯作者:
    Saijun Fan
Microbeam radiation therapy: tissue dose penetration and BANG-gel dosimetry of thick-beams' array interlacing.
微束放射治疗:组织剂量穿透和厚束阵列交错的 BANG-gel 剂量测定。
  • DOI:
    10.1016/j.ejrad.2008.04.055
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    F. Dilmanian;P. Romanelli;Z. Zhong;Ruiliang Wang;Mark E Wagshul;J. Kalef;Marek J. Maryanski;Eliot M. Rosen;David J. Anschel
  • 通讯作者:
    David J. Anschel
Response of rat intracranial 9 L gliosarcoma to microbeam radiation therapy 1
大鼠颅内9L胶质肉瘤对微束放射治疗的反应1
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    F. Dilmanian;T. Button;Géraldine Le Duc;Nan Zhong;Louis A. Peña;Jennifer A. L. Smith;Steve R. Martinez;T. Bacarian;J. Tammam;Baorui Ren;Peter M. Farmer;John Kalef;P. Micca;M. Nawrocky;James A. Niederer;F. Recksiek;Alexander Fuchs;Eliot M. Rosen
  • 通讯作者:
    Eliot M. Rosen

Eliot M. Rosen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eliot M. Rosen', 18)}}的其他基金

Development of BRCA1-mimetic drugs for breast cancer
乳腺癌 BRCA1 模拟药物的开发
  • 批准号:
    8403554
  • 财政年份:
    2010
  • 资助金额:
    $ 41.15万
  • 项目类别:
Development of BRCA1-mimetic drugs for breast cancer
乳腺癌 BRCA1 模拟药物的开发
  • 批准号:
    8610151
  • 财政年份:
    2010
  • 资助金额:
    $ 41.15万
  • 项目类别:
Development of BRCA1-mimetic drugs for breast cancer
乳腺癌 BRCA1 模拟药物的开发
  • 批准号:
    8022946
  • 财政年份:
    2010
  • 资助金额:
    $ 41.15万
  • 项目类别:
Development of BRCA1-mimetic drugs for breast cancer
乳腺癌 BRCA1 模拟药物的开发
  • 批准号:
    8207275
  • 财政年份:
    2010
  • 资助金额:
    $ 41.15万
  • 项目类别:
BRCA Genes in Breast Cancer Chemoprevention
BRCA 基因在乳腺癌化学预防中的作用
  • 批准号:
    6925842
  • 财政年份:
    2005
  • 资助金额:
    $ 41.15万
  • 项目类别:
BRCA Genes in Breast Cancer Chemoprevention
BRCA 基因在乳腺癌化学预防中的作用
  • 批准号:
    7024493
  • 财政年份:
    2005
  • 资助金额:
    $ 41.15万
  • 项目类别:
BRCA Genes in Breast Cancer Chemoprevention
BRCA 基因在乳腺癌化学预防中的作用
  • 批准号:
    7614406
  • 财政年份:
    2005
  • 资助金额:
    $ 41.15万
  • 项目类别:
BRCA Genes in Breast Cancer Chemoprevention
BRCA 基因在乳腺癌化学预防中的作用
  • 批准号:
    7227848
  • 财政年份:
    2005
  • 资助金额:
    $ 41.15万
  • 项目类别:
BRCA Genes in Breast Cancer Chemoprevention
BRCA 基因在乳腺癌化学预防中的作用
  • 批准号:
    7416594
  • 财政年份:
    2005
  • 资助金额:
    $ 41.15万
  • 项目类别:
ROLE OF BRCA1 AS A HUMAN PROSTATE SUPPRESSOR GENE
BRCA1 作为人类前列腺抑制基因的作用
  • 批准号:
    6173750
  • 财政年份:
    1999
  • 资助金额:
    $ 41.15万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.15万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了